Drugs that contain Cetirizine Hydrochloride
1. List of Quzyttir drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8513259 | JDP | Non-sedating antihistamine injection formulations and methods of use thereof |
Feb, 2030
(7 years from now) | |
| US9180090 | JDP | Non-sedating antihistamine injection formulations and methods of use thereof |
Feb, 2030
(7 years from now) | |
| US9119771 | JDP | Non-sedating antihistamine injection formulations and methods of use thereof |
Feb, 2030
(7 years from now) | |
| US8314083 | JDP | Non-sedating antihistamine injection formulations and methods of use thereof |
Feb, 2030
(7 years from now) | |
| US8263581 | JDP | Non-sedating antihistamine injection formulations and methods of use thereof |
Feb, 2030
(7 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Oct 4, 2022 |
Market Authorisation Date: 04 October, 2019
Treatment: Method of increasing peak plasma or onset of plasma concentration by intravenous injection in individuals in need of treatment for acute urticaria; Treatment of acute urticaria; Method of treatment in patients with concomitant angioedema
Dosage: SOLUTION;INTRAVENOUS
2. List of Zerviate drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9993471 | EYEVANCE | Ophthalmic formulations of cetirizine and methods of use |
Mar, 2030
(7 years from now) | |
| US8829005 | EYEVANCE | Ophthalmic formulations of cetirizine and methods of use |
Mar, 2030
(7 years from now) | |
| US9750684 | EYEVANCE | Ophthalmic formulations of cetirizine and methods of use |
Mar, 2030
(7 years from now) | |
|
US8829005
(Pediatric) | EYEVANCE | Ophthalmic formulations of cetirizine and methods of use |
Sep, 2030
(7 years from now) | |
| US9254286 | EYEVANCE | Ophthalmic formulations of cetirizine and methods of use |
Jul, 2032
(9 years from now) | |
|
US9254286
(Pediatric) | EYEVANCE | Ophthalmic formulations of cetirizine and methods of use |
Jan, 2033
(9 years from now) | |
Market Authorisation Date: 30 May, 2017
Treatment: Treatment of ocular itching associated with allergic conjunctivitis
Dosage: SOLUTION/DROPS;OPHTHALMIC
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic